Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts (AMLX)

Summary by Seeking Alpha
Amylyx Pharmaceuticals, Inc. upgraded to Strong Buy after phase 3 LUCIDITY avexitide PBH results. Click for this AMLX stock update and see why I am upgrading it.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts (AMLX)

Amylyx Pharmaceuticals, Inc. upgraded to Strong Buy after phase 3 LUCIDITY avexitide PBH results. Click for this AMLX stock update and see why I am upgrading it.

·Ra'anana, Israel
Read Full Article
IBTimes AustraliaIBTimes Australia

Amylyx Pharmaceuticals Stock Soars 48% After Avexitide Hits All Endpoints in Pivotal Phase 3 Trial

Amylyx Pharmaceuticals' shares soared 48% after announcing positive Phase 3 trial results for avexitide, a drug targeting post-bariatric hypoglycemia, marking a significant milestone for the biotech company.

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

IBTimes Australia broke the news in New York, United States on Tuesday, August 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Technology icon

Technology

Oceania icon

Oceania

Australia icon

Australia

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal